<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048706</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003725</org_study_id>
    <nct_id>NCT05048706</nct_id>
  </id_info>
  <brief_title>SP TLF Versus Ho:YAG Laser</brief_title>
  <official_title>Comparative Effectiveness of the Super Pulse Thulium Fiber Laser (SP TLF) for Laser Lithotripsy of Urinary Calculi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to compare the performance of the Super Pulse Thulium fiber laser (SP TFL)with that of&#xD;
      the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser. We hypothesize that the&#xD;
      electronically-modulated laser diodes, of the TFL offers the most comprehensive and flexible&#xD;
      range of laser parameters among laser lithotripters [1]. leading to more efficient (4 times&#xD;
      more) and effective stone dusting resulting in production of finer dust particles obviating&#xD;
      the need for postoperative ureteric stenting which remains a major source of patient&#xD;
      discomfort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the efficiency of SP TFL in dusting stones</measure>
    <time_frame>6 months</time_frame>
    <description>We plan to assess the direct impact of SP TFL to efficiently dust 10-30mm stones in the upper urinary tract . Metrics include time needed to ablate the stone i.e. ablation speed (stone volume mm3/sec)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean ablation energy needed to ablate stone volume</measure>
    <time_frame>6 months</time_frame>
    <description>We plan to assess the direct impact of SP TFL to effectively dust 10-30mm stones in the upper urinary tract . Metrics include ablation energy needed to ablate the stone volume (Stone volume mm3/Joules)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of stones cleared.</measure>
    <time_frame>9 months</time_frame>
    <description>We plan to assess the direct impact of SP TFL to produce finer quality dust following disregarding of 10-30mm stones in the upper urinary tract that can spontaneously pass without the need for stenting . Metrics will be stone clearance on postoperative CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reporting complications.</measure>
    <time_frame>9 months</time_frame>
    <description>We plan to assess the direct impact of SP TFL to safely dust 10-30mm stones in the upper urinary tract . Metrics collected will include review of medical record for the presence of complications (e.g. infection, sepsis, obstruction etc.) for 3 months postoperative related to laser lithotripsy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urinary Calculi</condition>
  <arm_group>
    <arm_group_label>Super Pulse Thulium fiber Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Holmium: Yttrium-Aluminium-Garnet Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser lithotripsy (SP TLF)</intervention_name>
    <description>Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)</description>
    <arm_group_label>Super Pulse Thulium fiber Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser lithotripsy (Ho:YAG)</intervention_name>
    <description>Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.</description>
    <arm_group_label>Holmium: Yttrium-Aluminium-Garnet Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is scheduled to undergo mini-PCNL and/or RIRS surgery at the University of&#xD;
             Rochester Medical Center for the management of upper urinary tract calculi (i.e.&#xD;
             kidney and proximal ureter)&#xD;
&#xD;
          -  Stones located in the kidney and proximal ureter&#xD;
&#xD;
          -  Stones measuring 10-30mm&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
          -  Any racial or ethnic origin&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active kidney infection&#xD;
&#xD;
          -  Patients with prior stenting&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Patients with solitary kidney&#xD;
&#xD;
          -  Patients with ureteral tumor or stricture&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
&#xD;
          -  Not age 18 and older&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Ghazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Ghazi, MD</last_name>
    <phone>585-424-6491</phone>
    <email>ahmed_ghazi@urmc.rochester.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tyler Holler, MPH</last_name>
    <phone>585-276-3063</phone>
    <email>tyler_holler@urmc.rochester.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed Ghazi, MD</last_name>
      <phone>585-424-6491</phone>
      <email>ahmed_ghazi@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tyler Holler, MPH</last_name>
      <phone>585-276-3063</phone>
      <email>tyler_holler@urmc.rochester.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ahmed Ghazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rajat Jain, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Quarrier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Ahmed Ghazi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

